{"a":[{"_":"Biogen flips '26 guidance from expected decline to sales increase","$":{"href":"/pharma/biogen-flips-its-26-guidance-expected-decline-increase","hreflang":"en"}}]}

Summary

Biogen raised its 2026 revenue guidance from an expected mid-single digit decline to a mid-single digit increase, driven by growth in newer drugs offsetting declining multiple sclerosis portfolio revenues, positioning the company for renewed growth.